已收盘 02-06 16:00:00 美东时间
+0.670
+3.67%
华盛资讯2月7日讯,国民油井华高公布2025财年Q4业绩,公司Q4营收22.77亿美元,同比下降1.3%,归母净利润亏损0.78亿美元,由盈转亏。
今天 00:54
今日重点评级关注:韦德布什:维持Replimune Group"跑赢大市"评级,目标价从18美元升至19美元;巴克莱:维持CytomX Therapeutics"超配"评级,目标价从8美元升至10美元
02-05 11:28
NOV (NYSE:NOV) sees Q1 sales of $2.124 billion-$2.168 billion vs $2.044 billion analyst estimate.
02-05 06:20
NOV Inc. (NOV) +2.2% in Wednesday's trading as Barclays upgraded the energy equipment and services company to Equal Weight from Underweight with a $20 price target, raised from $15, as new CEO Jose Ba...
02-05 03:46
Barclays analyst David Anderson upgrades NOV (NYSE:NOV) from Underweight to Equal-Weight and raises the price target from $15 to $20.
02-04 21:53
今日重点评级关注:Needham:维持Vaxcyte"买入"评级,目标价从90美元升至110美元;Citizens: 维持LGI Homes"跑赢大市"评级,目标价从85美元升至95美元
01-08 18:33
Susquehanna analyst Charles Minervino maintains NOV (NYSE:NOV) with a Positive and raises the price target from $17 to $20.
01-08 01:36
今日重点评级关注:Ascendiant Capital:维持Society Pass"买入"评级,目标价从22美元升至22.5美元;HC Wainwright & Co.:维持Climb Bio"买入"评级,目标价从9美元升至11美元
2025-12-19 10:15
Piper Sandler analyst Luke Lemoine maintains NOV (NYSE:NOV) with a Neutral and raises the price target from $14 to $17.
2025-12-18 20:21
今日重点评级关注:巴克莱:维持Iovance Biotherapeutics"超配"评级,目标价从9美元升至10美元;摩根大通:上调Recursion Pharmaceuticals评级至"超配",目标价从10美元升至11美元
2025-12-18 10:54